Professor Meg Jardine is the Director of the NHMRC Clinical Trials Centre, the University of Sydney and Lead of the Kidney Health Research Program. Her research has focussed on investigating the progression and complications of non-communicable diseases, particularly kidney disease and diabetes, through randomised trials and epidemiological analyses. She has experience in the design and conduct of national and international trials.

Prof Jardine has a particular interest in expanding the use of innovative and cost-effective methodologies to increase the generation of high-quality evidence. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to their efficient delivery. Prof Jardine is a member of the Executive Committees of both the International Society of Nephrology (ISN) and of the Kidney Disease Improving Global Outcomes (KDIGO) international nephrology guidelines body. She is Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) initiative. She serves as a Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US (United States) FDA (Food and Drug Administration).

She is a Board member of the Australian Clinical Trials Alliance (ACTA) and a member of the ANZSN (Australia and New Zealand Society of Nephrology) Research Advisory Committee. Prof Jardine is a specialist nephrologist at Concord Repatriation General Hospital and a proud recipient of the Australian and New Zealand Society of Nephrology T.J.Neale award for Outstanding Contribution to Nephrological Science